Amgen Surpasses Q4 Earnings Forecasts
Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.
Amgen down 2% after earnings, clinical hold on obesity study
Shares of Amgen (AMGN) are down $6.62, or 2%, to $282.40 in after-hours trading.Maximize Your Portfolio with Data Driven Insights:Leverage the
Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amgen: Q4 Earnings Snapshot
The Thousand Oaks, California-based company said it had net income of $1.16 per share. Earnings, adjusted for non-recurring costs, came to $5.31 per share. The results surpassed Wall Street expectations. The average estimate of 13 analysts surveyed by Zacks Investment Research was for earnings of $5.03 per share.
Amgen’s (NASDAQ:AMGN) Q4 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations
Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2024 results , with sales up 10.9% year on year to $9.09 billion. The company’s full-year revenue guidance of $35 billion at the midpoint came in 1.4% above analysts’ estimates.
Amgen (AMGN) Q4 Earnings and Revenues Surpass Estimates
Amgen (AMGN) came out with quarterly earnings of $5.31 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $4.71 per share a year ago. These figures are adjusted for non-recurring items.
Amgen Q4 Earnings Preview: Street expects revenue to rise more than 8%
Biopharmaceutical company Amgen (AMGN) is set to announce its fourth quarter earnings results on Tuesday, February 4th, after the closing bell. Wall Street expe
Amgen profit beats estimates, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
AMGN Earnings: Amgen Slips on Soft EPS Guidance
Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...
Hosted on MSN5h
Amgen Skids On A Surprise Setback For One Of Its Obesity Drugs
Amgen stock skidded late Tuesday after the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...
STAT5h
Study of Amgen’s early obesity candidate paused by FDA
The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...
These Were the 5 Top-Performing Stocks in the Dow Jones Industrial Average in January 2025
Industrial company 3M ( MMM 1.15%) was the index's top performer in January with a 17.9% gain. Part of the stock's movement ...
Amgen profits rise, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains
Product sales rose 11%, led by 14% volume growth. Products including Repatha, Blincyto and Tezspire all posted at least double digit sales growth, the company said. For the current year, Amgen expects ...
Open Source: Amgen CEO credited new NC factory to Trump tax cuts. Is he right?
The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake ...
Amgen targets $34.3B-$35.7B in 2025 revenues with strong growth in key therapeutic areas
Q4 2024 Management View Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert Bradway emphasized the company's resilience in ...